Press "Enter" to skip to content

FDA approves new treatment for hospital-acquired and ventilator-associated bacterial pneumonia

FDA today approved a new indication for the previously FDA-approved drug, Zerbaxa (ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older.

Original source: http://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hospital-acquired-and-ventilator-associated-bacterial-pneumonia

Also Read:   Statement on FDA’s new report regarding root causes and potential solutions to drug shortages